EGFR and non-small cell lung carcinoma: In recent years, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are clinically effective in patients with non–small cell lung cancer (NSCLC) harboring sensitizing EGFR mutations.